Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

KYTX

Kyverna Therapeutics Inc

Jun 12 • 02:43PM ET

3.53

Dollar change +0.22
Percentage change 6.65	%

Healthcare • Biotechnology • USA • NASD

Peers: MRNA AMGN VRTX JNJ REGN GILD BMRN PFE BMY NVAX

| Held by: IWM VTI VXF IWO IBB SCHA VTWO IWN IWC SBIO

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-3.37	Insider Own	54.98%	Shs Outstand	43.22M	Perf Week	20.07%
Market Cap	152.56M	Forward P/E	-	EPS next Y	-3.15	Insider Trans	0.00%	Shs Float	19.45M	Perf Month	52.16%
Income	-145.42M	PEG	-	EPS next Q	-1.04	Inst Own	25.51%	Short Float	10.75%	Perf Quarter	41.20%
Sales	0.00M	P/S	-	EPS this Y	-11.70%	Inst Trans	-15.72%	Short Ratio	6.26	Perf Half Y	-27.37%
Book/sh	5.18	P/B	0.68	EPS next Y	15.42%	ROA	-44.70%	Short Interest	2.09M	Perf Year	-73.89%
Cash/sh	5.61	P/C	0.63	EPS next 5Y	-2.34%	ROE	-49.72%	52W Range	1.78 - 16.64	Perf YTD	-5.61%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROIC	-63.96%	52W High	-78.79%	Beta	2.71
Dividend TTM	-	Quick Ratio	7.44	Sales past 5Y	-	Gross Margin	-	52W Low	98.31%	ATR (14)	0.30
Dividend Ex-Date	-	Current Ratio	7.44	EPS Y/Y TTM	-48.62%	Oper. Margin	-	RSI (14)	68.98	Volatility	9.30% 7.82%
Employees	112	Debt/Eq	0.03	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	17.20
Option/Short	Yes / Yes	LT Debt/Eq	0.01	EPS Q/Q	8.09%	Payout	-	Rel Volume	1.17	Prev Close	3.31
Sales Surprise	-	EPS Surprise	8.50%	Sales Q/Q	-	Earnings	May 13 AMC	Avg Volume	334.22K	Price	3.53
SMA20	29.00%	SMA50	51.08%	SMA200	-8.77%	Trades		Volume	317,095	Change	6.65%

Date	Action	Analyst	Rating Change	Price Target Change
May-27-25	Upgrade	H.C. Wainwright	Neutral → Buy	$5
Oct-10-24	Initiated	UBS	Buy	$13
Oct-09-24	Initiated	Rodman & Renshaw	Buy	$16
Jul-03-24	Initiated	H.C. Wainwright	Neutral	$8
Mar-04-24	Initiated	Wells Fargo	Overweight	$44
Mar-04-24	Initiated	Morgan Stanley	Overweight	$40
Mar-04-24	Initiated	Leerink Partners	Outperform	$48
Mar-04-24	Initiated	JP Morgan	Overweight	$39

May-28-25 04:02PM	Kyverna Therapeutics to Present at the Jefferies Global Healthcare Conference (PR Newswire)
May-16-25 06:36AM	Regeneron defeats Amgen in PCSK9 case; 2 cell therapy biotechs cut staff (BioPharma Dive) +6.42%
May-13-25 04:02PM	Kyverna Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results (PR Newswire) -7.33%
Apr-17-25 07:38AM	Notice to Long-Term Shareholders of Kyverna Therapeutics, Inc. (NASDAQ: KYTX); Methode Electronics, Inc. (NYSE: MEI); ModivCare, Inc. (NASDAQ: MODV); and Monolithic Power Systems, Inc. (NASDAQ: MPWR) - Grabar Law Office Is Investigating Claims on Your Behalf (GlobeNewswire)
Mar-27-25 04:02PM	Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results (PR Newswire) -5.80% -15.07%
09:13AM	Loading…
Mar-24-25 09:13AM	Notice to Long-Term Shareholders of Akero Therapeutics, Inc. (Nasdaq: AKRO); Driven Brands Holdings, Inc. (Nasdaq: DRVN); Integra Lifesciences Holdings Corporation (Nasdaq: IART); and Kyverna Therapeutics, Inc. (Nasdaq: KYTX): Grabar Law Office is Investigating Claims on Your Behalf (GlobeNewswire)
Mar-21-25 11:29AM	Kyverna: 2 Myasthenia Gravis Program Catalysts On Deck In 2025 (SeekingAlpha)
08:32AM	Notice to Long-Term Shareholders of Driven Brands Holdings, Inc. (NASDAQ: DRVN); Kyverna Therapeutics, Inc. (NASDAQ: KYTX); Mercury Systems, Inc. (NASDAQ: MRCY); and Rocket Lab USA, Inc. (NASDAQ: RKLB): Grabar Law Office is Investigating Claims on Your Behalf (GlobeNewswire)
Mar-18-25 04:48PM	Notice to Long-Term Shareholders of Archer-Daniels-Midland Co. (NYSE: ADM); Driven Brands Holdings, Inc. (Nasdaq: DRVN); Kyverna Therapeutics, Inc. (Nasdaq: KYTX); and Mercury Systems, Inc. (Nasdaq: MRCY): Grabar Law Office is Investigating Claims on Your Behalf (GlobeNewswire)
Mar-17-25 03:01PM	Notice to Long-Term Shareholders of Fluence Energy, Inc. (NASDAQ: FLNC); Kyverna Therapuetics, Inc. (NASDAQ: KYTX); Mercury Systems, Inc. (NASDAQ: MRCY); and Sage Therapeutics, Inc. (NASDAQ: SAGE): Grabar Law Office Is Investigating Claims on Your Behalf (GlobeNewswire)
Mar-03-25 04:05PM	Kyverna Therapeutics to Present at the Leerink Partners Global Biopharma Conference (PR Newswire) -8.80%
Feb-10-25 12:00PM	What Makes Kyverna Therapeutics, Inc. (KYTX) a New Buy Stock (Zacks)
Jan-21-25 04:05PM	Kyverna Therapeutics Appoints Naji Gehchan, MD, MBA, as Chief Medical and Development Officer (PR Newswire)
Jan-17-25 05:45AM	Kyverna Therapeutics, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before February 7, 2025 to Discuss Your Rights - KYTX (PR Newswire)
Jan-13-25 07:30AM	Kyverna Therapeutics to Highlight Near-Term Strategic Priorities and Key Milestones at the 43rd Annual J.P. Morgan Healthcare Conference (PR Newswire)
08:00AM	Loading…
Jan-08-25 08:00AM	Unnatural Products Appoints Abbas Kazimi and Mert Aktar to Board of Directors (GlobeNewswire)
Jan-07-25 05:45AM	Kyverna Therapeutics, Inc. Sued for Securities Law Violations - Contact Levi and Korsinsky Before February 7, 2025 to Discuss Your Rights - KYTX (PR Newswire)
Jan-06-25 04:05PM	Kyverna Therapeutics to Present at the 43rd Annual J. P. Morgan Healthcare Conference (PR Newswire) -7.07%
Dec-27-24 05:45AM	Kyverna Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi and Korsinsky Before February 7, 2025 to Discuss Your Rights - KYTX (PR Newswire)
Dec-19-24 12:16PM	Investors in Kyverna Therapeutics, Inc. Should Contact Levi and Korsinsky Before February 7, 2025 to Discuss Your Rights KYTX (GlobeNewswire)
Dec-13-24 04:05PM	Kyverna Therapeutics Strengthens Leadership Team to Accelerate Next Phase of Growth (PR Newswire)
Dec-09-24 06:38PM	Kyverna Therapeutics, Inc. Investors Who Have Lost Money Should Contact Block and Leviton to Find Out How They Might Recover Money Through A Recent Securities Lawsuit (GlobeNewswire) +6.81% -5.56%
Nov-14-24 10:01AM	Kyverna Therapeutics Announces New Patient Data Highlighting Potential of KYV-101 for Treatment of Lupus Nephritis in Symposium at ACR Convergence 2024 (PR Newswire) -5.14%
Nov-13-24 04:14PM	Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results (PR Newswire)
Oct-21-24 08:00AM	Kyverna Therapeutics Appoints Mert Aktar to its Board of Directors (PR Newswire) -7.80%
Oct-19-24 11:13AM	Kyverna Therapeutics (KYTX): Leading Nano Cap with Promising CAR T-Cell Therapy (Insider Monkey)
Oct-10-24 03:05PM	JPMorgan Chase & Co's Strategic Acquisition in Kyverna Therapeutics Inc (GuruFocus.com)
Sep-18-24 08:00AM	Kyverna Therapeutics Presents Patient Data Reinforcing Potential of KYV-101 for Treatment of Neuroinflammatory Diseases in Symposium at ECTRIMS 2024 (PR Newswire)
Sep-16-24 08:00AM	Kyverna Therapeutics Announces Leadership Update (PR Newswire)
06:58AM	Kyverna swaps CEOs, leaning on Kite veterans to lead next chapter (BioPharma Dive)
04:05PM	Loading…
Aug-21-24 04:05PM	Kyverna Therapeutics to Participate in Upcoming September Investor Conferences (PR Newswire) +13.36% -5.36%
Aug-12-24 04:08PM	Kyverna Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results (PR Newswire) +7.20%
04:05PM	Kyverna Therapeutics Receives U.S. FDA RMAT Designation for KYV-101 in the Treatment of Patients With Progressive Myasthenia Gravis (PR Newswire)
Jul-16-24 11:33AM	Kyverna wins RMAT designation for stiff-person syndrome for cell therapy candidate (Pharmaceutical Technology) +11.71%
08:52AM	Kyverna (KYTX) Gets RMAT Designation for CAR T-Cell Product (Zacks)
Jul-15-24 04:05PM	Kyverna's KYV-101 Receives U.S. FDA RMAT Designation for KYV-101 in the Treatment of Patients With Refractory Stiff-Person Syndrome (PR Newswire)
Jun-20-24 08:55AM	Kyverna's KYV-101 Receives U.S. FDA IND Clearance for Treatment of Patients With Treatment-Refractory Stiff-Person Syndrome in the KYSA-8 Phase 2 Trial (PR Newswire) +7.93%
Jun-17-24 04:05PM	First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patient With Severe Stiff-Person Syndrome Published in Proceedings of the National Academy of Sciences (PNAS) (PR Newswire) -17.21% -5.70%
Jun-10-24 04:05PM	Kyverna Therapeutics and National Institutes of Health Co-Author Seminal Review on Cell Therapy for Autoimmunity in Nature Reviews Immunology (PR Newswire)
Jun-07-24 08:55AM	Kyverna Therapeutics to Present Data on 50 Patient Experience at Symposium at EULAR 2024 (PR Newswire)
May-14-24 10:54PM	KYTX Stock Earnings: Kyverna Therapeutics Misses EPS for Q1 2024 (InvestorPlace) +5.95%
04:05PM	Kyverna Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results (PR Newswire)
Apr-11-24 05:01PM	Kyverna Therapeutics to attend the 2024 American Academy of Neurology (AAN) Annual Meeting in Denver, CO, With Data on KYV-101 in the Treatment of Patients with Neurological Autoimmune Diseases (PR Newswire)
Mar-29-24 02:59PM	First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patients With Progressive Multiple Sclerosis Published in Med (PR Newswire)
Mar-26-24 04:05PM	Kyverna Therapeutics Provides Business Update and Reports Full Year 2023 Financial Results (PR Newswire) +6.97%
Mar-14-24 07:00AM	Why That Hot Biotech IPO Could Be a Winner (The Wall Street Journal)
Mar-07-24 07:26PM	Kyverna Therapeutics and Stanford University Agree to Evaluate KYV-101 in Patients with Non-Relapsing and Progressive Forms of Multiple Sclerosis (PR Newswire)
06:14PM	How Kyverna is positioned for success on autoimmune therapy: CEO (Yahoo Finance Video)
Feb-12-24 04:39PM	Kyverna Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares (PR Newswire)
Feb-07-24 10:29PM	Kyverna Therapeutics Announces Pricing of Upsized Initial Public Offering (PR Newswire)

Kyverna Therapeutics, Inc. is a cell therapy clinical-stage biotechnology company, which engages in the provision of treatments and potential cures for serious autoimmune diseases. The company was founded in June 2018 and is headquartered in Emeryville, CA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

KYTX

Kyverna Therapeutics Inc

Upgrade your FINVIZ experience